Ruffer LLP Sells 37,809 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Ruffer LLP lowered its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 34.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,807 shares of the biopharmaceutical company’s stock after selling 37,809 shares during the quarter. Ruffer LLP owned about 0.06% of Catalyst Pharmaceuticals worth $1,655,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Catalyst Pharmaceuticals by 30.0% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 167,763 shares of the biopharmaceutical company’s stock valued at $3,913,000 after acquiring an additional 38,695 shares in the last quarter. Round Rock Advisors LLC increased its holdings in shares of Catalyst Pharmaceuticals by 28.9% during the fourth quarter. Round Rock Advisors LLC now owns 32,357 shares of the biopharmaceutical company’s stock valued at $755,000 after acquiring an additional 7,247 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Catalyst Pharmaceuticals by 28.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 48,643 shares of the biopharmaceutical company’s stock valued at $1,135,000 after acquiring an additional 10,749 shares in the last quarter. First Horizon Corp acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $52,000. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $111,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 1.2%

Shares of NASDAQ:CPRX opened at $25.94 on Thursday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $26.58. The company’s 50 day moving average is $24.42 and its 200 day moving average is $23.37. The company has a market cap of $3.17 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 0.74 and a beta of 0.67.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CPRX. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Zacks Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Citigroup upped their price objective on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Strong Buy” and a consensus price target of $34.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).